Vmbook Online ordering
Mead Johnson Nutrition Company
Mead Johnson Nutrition Company was a public company that was listed on the New York Stock Exchange under the ticker symbol MJN. The company was a global leader in infant and children's nutrition, developing and marketing products such as Enfamil and Nutramigen.
Here's some general information about Mead Johnson Nutrition Company:
* Founded: 1886
* headquarters: Glenview, Illinois, United States
* Industry: Infant and children's nutrition
* Revenue: $3.7 billion (2016)
* Net income: $442.3 million (2016)
* Stock symbol: MJN (NYSE)
In terms of earnings, Mead Johnson Nutrition Company had a strong track record of delivering consistent profitability. In 2016, the company reported net sales of $3.7 billion, up 4% from the previous year. Net income for 2016 was $442.3 million, up 11% from the previous year.
Mead Johnson Nutrition Company had a strong history of growing its earnings and revenue over the years. The company's focus on innovation, brand recognition, and global reach helped it to maintain its position as a leader in the infant and children's nutrition industry.
In 2017, Mead Johnson Nutrition Company was acquired by Reckitt Benckiser, a British multinational consumer goods company, for $16.7 billion. The acquisition marked the end of Mead Johnson Nutrition Company's independence, but it also provided the company with access to greater resources and a global platform for growth.
It's worth noting that the company's financial performance and growth prospects were impacted by various factors such as competitive pressure, regulatory changes, and economic conditions. Additionally, Mead Johnson Nutrition Company faced challenges such as product recalls and supply chain disruptions, which could have affected its financial performance.
Overall, Mead Johnson Nutrition Company had a long history of delivering strong financial performance and growth, with a focus on innovation, brand recognition, and global reach. However, the company's financial performance was not immune to challenges and risks from the competitive and regulatory environment.